ADIPOPLUS — Competitive Intelligence Brief

ADIPOPLUS (ADIPOPLUS) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SIRT1 activator. Area: Diabetes.

phase 2 SIRT1 activator SIRT1 Diabetes Biologic

Target snapshot

ADIPOPLUS (ADIPOPLUS) — Anterogen Co., Ltd.. ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADIPOPLUS TARGET	ADIPOPLUS	Anterogen Co., Ltd.	phase 2	SIRT1 activator	SIRT1
Resveratrol Pill	Resveratrol Pill	Russian Academy of Medical Sciences	marketed	Natural polyphenol / Sirtuin activator	SIRT1, antioxidant pathways, NF-κB
oral resveratrol	oral resveratrol	Assistance Publique - Hôpitaux de Paris	phase 3	polyphenol	SIRT1
Resveratrol nasal spray	Resveratrol nasal spray	University of Campania Luigi Vanvitelli	phase 3	Polyphenolic antioxidant	SIRT1, NF-κB pathway
Mega Resveratrol® capsules	Mega Resveratrol® capsules	Sun Yat-sen University	phase 3	Polyphenolic antioxidant / Sirtuin activator	SIRT1, general antioxidant pathways, AMPK

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SIRT1 activator class)

1. Anterogen Co., Ltd. · 1 drug in this class